For example, a phase I study in patients with solid tumors such as breast and ovarian cancers, evaluated Emactuzumab, an anti-CSF1R treatment, in combination with paclitaxel chemotherapy (Figure 2B). Here, CSF1R is linked to ovarian cancer.